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RESEARCH NOTE
Summary. Colonic infection with Clostridium difficile, leading to pseudomem-
branous colitis, is a common complication of antibiotic therapy, especially in eld-
erly patients. It has been suggested that non-pathogenic probiotic bacteria might
prevent the development and recurrence of C. difficile infection. This double-blind,
placebo-controlled study examines the role of probiotic administration in the pre-
vention of C. difficile-associated diarrhoea (CDAD) in elderly patients receiving
antibiotic therapy. Consecutive patients (150) receiving antibiotic therapy were
randomised to receive either a probiotic containing both Lactobacillus and
Bifidobacterium or placebo for 20 days. Upon admission to hospital, bowel habit
was recorded and a faecal sample taken. Trial probiotic or placebo was taken
within 72 h of prescription of antibiotics, and a second stool sample was taken in
the event of development of diarrhoea during hospitalisation or after discharge. Of
the randomised patients, 138 completed the study, 69 with probiotics in conjunc-
tion with antibiotics and 69 with antibiotics alone. On the basis of development of
diarrhoea, the incidence of samples positive for C. difficile-associated toxins was
2.9% in the probiotic group compared with 7.25% in the placebo-control group.
When samples from all patients were tested (rather than just those developing diar-
rhoea) 46% of probiotic patients were toxin-positive compared with 78% of the
placebo group. [Int Microbiol 2004; 7(1):59–62]
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Introduction
Clostridium difficile is a gram-positive, anaerobic bacillus
that colonises the human large intestine, and produces at least
two exotoxins: toxin A, which is primarily an enterotoxin,
and toxin B, a cytotoxin. Colonisation by this organism and
subsequent infection occur in response to disruption of the
stability of the indigenous microflora. The altered colonisa-
tion resistance frequently occurs following antibiotic therapy
in hospitalised patients [12]. Finegold [4] claimed that all
antimicrobial agents (with the exception of vancomycin and
parenterally administered aminoglycosides) have been docu-
mented as pre-disposing patients to susceptibility to C. diffi-
cile infection. Responses to colonisation of the large intestine
by C. difficile vary from asymptomatic, to mild diarrhoea,
through to pseudomembranous colitis.
C. difficile is one of the most common causes of infec-
tious diarrhoea in hospitals and nursing homes [10] and is the
leading cause of nosocomially acquired intestinal infections
in the USA [16]. Within hospitals, the extensive use of antibi-
otics, together with the inherent environmental contamina-
tion provides sources of cross-infection. Prevalence of C. dif-
ficile in the general environment is far lower than in health-
care facilities. A single case of C. difficile-associated diar-
rhoea per 15,000 out-patients has been recorded, but up to
20% of in-patients may be colonised by C. difficile.
The financial burden associated with C. difficile infections
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is substantial for hospitals. Recurrence of symptoms follow-
ing treatment of the infection is a particular problem with 5 to
66% of patients suffering from recurrences [16,18]. Jones and
MacGowan [7] stated that, despite the issue of guidelines
[DoH/PHLS, 1994 (Department of Health/Public Health
Laboratory Service)] regarding the management and preven-
tion of C. difficile infections, the problems continue and the
authors suggested that the prophylactic use of biotherapies
might be necessary to increase colonisation resistance.
Biotherapy (therapy involving probiotics) is emerging as
a potential means of controlling C. difficile diarrhoeal recur-
rences, and promising results have been found when a stool
sample was directly donated by colonoscopy [14] and when
a non-pathogenic yeast (Saccharomyces boulardii) was used
to treat C. difficile-infected rats and rabbits [2]. The role of
the probiotic organisms is to restore the colonisation resist-
ance of the normal flora, disrupted by the effects of antibiotic
therapy, in order to prevent re-infection by C. difficile [9]. In
this study, the emphasis is on the use of the probiotic product
to prevent the initial infection and, thereby, minimise cross
contamination and contain the spread of infection.
Materials and methods
Trial design. The trial was a double blind, placebo-controlled study in the
departments of medicine and medicine for the elderly at Addenbrooke’s
Hospital, Cambridge. Patients with acute emergencies requiring treatment
with antibiotics participated in the study. Ethical approval was obtained from
the Cambridge Local Research Ethics Committee. Between March 1999 and
July 2000, 150 patients were recruited and 138 patients fulfilled the inclu-
sion criteria. For these patients, bowel habit on admission and prescribed
medication were recorded.
Randomisation. Trial participants were randomised on arrival at hospi-
tal (probiotic group 69, placebo group 69) and each patient received one cap-
sule/day for 20 days. The probiotic product (provided by Cultech, Swansea)
comprised 2×1010 cfu Lactobacillus acidophilus and Bifidobacterium
bifidum/capsule; the placebo comprised the inactive carrier. Trial treatments
started within 36 h of antibiotic prescription (1.12 days for patients taking
probiotics and 1.10 days for patients receiving placebo). Patients on a
course of antibiotics lasting longer than 20 days were withdrawn from the
trial, having had a final stool specimen collected.
Enumeration of Clostridium difficile. Faecal samples were enumer-
ated following alcohol shock treatment. Faecal material was mixed with
absolute alcohol (1:1, w/v), homogenised, and stored at 20°C for 60 min.
Dilution series set up anoxically in pre-reduced Maximum Recovery Diluent
(MRD, Oxoid, Basingstoke, UK) and appropriate dilutions plated onto
Clostridium difficile Agar (Oxoid) using a modified version (10×10 µl) of the
Miles and Misra plate count method [11]. Growth was recorded after 48 and
72 h incubation at 37°C. All presumptive C. difficile colonies were subcultured
onto anoxic blood agar for Gram staining, and all obligate anaerobic gram-pos-
itive rods were tested to confirm that they were catalase-negative. Colonies
were also tested using the Microscreen C. difficile Latex Slide Agglutination
test (Microgen Bioproducts, Camberley, Surrey, UK) and/or API ID32A
(Biomérieux, France). Samples positive for C. difficile were tested for the pres-
ence of C. difficile toxins A and B using an enzyme immunoassay kit
(Ridascreen C. difficile toxin A/B, R-Biopharm, Darmstadt, Germany).
Statistical analysis. The trial was set up on the basis of a power calcu-
lation which estimated that, for an expected incidence rate of C. difficile
infection of 10%, 400 patients would need to be recruited to show a 50% dif-
ference between the probiotic and the placebo in the prevention of C. diffi-
cile infection. The recruitment did not reach the required levels, which has
made statistical analysis of the data limited. The data have been analysed
using the methods of Newcombe [13] to determine confidence intervals for
differences between proportions..
Results and Discussion
On arrival in hospital, patients were randomly allocated to
receive probiotic or placebo in conjunction with their antibi-
otic therapy. Whilst on the ward, all episodes of diarrhoea
were recorded, as is normal practice, and samples were sent
to the hospital labs for typing. Unfortunately, it was not pos-
sible to achieve the required recruitment level during the
course of this study so the final numbers were lower than had
been indicated by the power calculation.
In addition to the standard hospital procedure of testing fol-
lowing the occurrence of diarrhoea, all participants in the trial
provided faecal samples for testing at the start of the trial and
following antibiotic therapy. On arrival at hospital, eight of the
138 participants (6%) were found to be carrying C. difficile
asymptomatically (Table 1) with only one developing diar-
rhoea whilst in hospital (patient 16, who arrived with high
numbers of C. difficile present). None of the patients tested
positive for C. difficile toxin on arrival. This more detailed
examination of the faecal samples from all patients (rather than
exclusively for the diarrhoea patients) indicated that the num-
bers of patients carrying C. difficile was comparable in both
groups, and such data (detailing presence of organisms) would
not be detected using standard procedures in the hospital.
Finegold [4] suggested that up to 3% of healthy adults
carry C. difficile, but many of the patients in this study may
have received antibiotic therapy prior to hospitalisation or
been hospitalised previously, which could have contributed to
the elevated carrier status. Linevsky and Kelly [10] suggested
that the asymptomatic carrier state may be due to toxin neutral-
isation rather than to the prevention of colonisation, as has
been found in animals [8]. During this study, it appeared that
there was an increase in C. difficile-associated problems fol-
lowing the admission of these asymptomatic carriers to hospi-
tal. In addition, the increase in the isolation rate of C. difficile
from patients following antibiotic therapy clearly indicated the
spread of this microorganism within the hospital environment.
Using the hospital-derived results to assess the 138
patients participating in the trial, 30 patients developed
symptoms of diarrhoea (22% incidence rate), 15 patients in
each treatment group. Analysis of the samples from these
patients showed that five patients in the placebo group and
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two of the patients in the probiotic group tested positive for
the presence of C. difficile toxin. Statistical analysis of these
results indicated that the proportion developing diarrhoea
positive for C. difficile-associated toxins was 4.35% lower in
the probiotic group (95% CI of –0.132 to 0.038).
There was a much greater proportion of patients positive
for the toxins in the placebo group than in the probiotic group
(which corresponds to the results obtained for diarrhoea
patients from the hospital labs). In the placebo group, there
appears to be a close relationship between the incidence of
diarrhoea and the presence of toxin but this was less apparent
among patients receiving probiotic. Thus, it would appear that
many of the patients receiving the probiotic product were in
the asymptomatic carrier state [10]. This may indicate the
potential mode of action of the probiotic, i.e. by achieving
some form of toxin neutralisation. Gorbach [6] found that
administration of Lactobacillus GG resulted in an increase in
the numbers of IgA- and other immunoglobulin-secreting cells
in the intestinal mucosa, producing an enhanced immune
response to the presence of C. difficile and/or its toxin. Such
a response could account for the greater incidence of asymp-
tomatic carriers observed among the probiotic group.
When the second faecal samples were analysed, C. diffi-
cile was detected in 20 of the 138 patients, four of whom had
tested C. difficile-positive on arrival. Nine of the patients
receiving placebo and 11 of the patients receiving probiotics
were carrying this organism (Table 2). Toxin testing of the
C. difficile-positive patients indicated that five of the 11 pro-
biotic patients (46%) were toxin-positive with two of the five
toxin-positive patients showing signs of diarrhoea. Seven of
the nine placebo patients carrying C. difficile (78%) were
toxin-positive, and six of these seven had diarrhoeal symp-
toms. Statistical analysis of the data obtained when all of the
samples were analysed indicated a 32% difference between
the detection of toxin among the C. difficile-positive placebo
group patients and the probiotic group patients (95% CI of
–0.096 to 0.61). There appeared to be an increased incidence
of C. difficile detection corresponding to the arrival of the
asymptomatic carriers at the hospital.
The fact that, more C. difficile-positive patients were
detected in the probiotic group than in the placebo group
again may support toxin neutralisation rather than prevention
of colonisation as the role of the probiotic organisms.
The participants in the trial were contacted following dis-
charge, and 14 of the patients reported incidences of diarrhoea
at home (9 placebo, 5 probiotic). Of these patients, however,
only one had tested positive for the presence of C. difficile
when the second faecal samples were analysed. In a trial with
Lactobacillus GG, Pochapin et al. [15] found that, for a group
of patients receiving either placebo or probiotic in conjunction
with their antibiotic therapy, 30% (3/10) of the patients in the
placebo group developed recurrent C. difficile-associated diar-
rhoea (CDAD) while none of the patients (0/6) in the probiot-
ic group suffered recurrent CDAD. However, for patients who
had previously suffered an episode of CDAD, the probiotic
product did not appear to exert any beneficial effect.
When the medical and financial implications of C. diffi-
cile diarrhoea were considered, Eriksson and Aronsson [3]
found that the median time for hospitalisation of the C. diffi-
cile patients was 50 days, compared with 14 days for unin-
fected controls. The mortality rates were 21% for the infect-
ed group and 7% for the control group (morbidity 14% and
4% respectively).
From the financial aspect, Spencer [17] suggested that the
major cost implications associated with C. difficile infec-
tion/outbreaks related to increased hospital stay, antibiotic
treatment, possible ward closure and loss of bed days to-
gether with infection control requirements. Wilcox et al. [18]
estimated that the average additional length of stay in hospi-
tal was 21.3 days longer for C. difficile patients, correspon-
ding to additional treatment costs per patient of £4,000. On
the basis of the hospital-derived results in this study, the five
placebo-group positive patients would have incurred an addi-
tional £20,000 expenditure whereas the probiotic group costs
would have been £8,000. If it is assumed that administration
of probiotic to all the patients in the trial incurred an addi-
tional cost of £2,000, the overall savings achieved from the
probiotic supplementation could have been £10,000, a 50%
reduction in costs.
PROBIOTIC SUPPLEMENTATION
Table 1. Patients presenting with Clostridium difficile on arrival at hospital
Patient Date of C. difficile viable
number admission number (cfu/g)
16 05/99 5.8×105
89 11/99 6.0×103
100 12/99 2.0×102
105 12/99 2.0×102
110 12/99 2.0×102
l13 01/00 6.0×103
119 01/00 4.0×102
136 03/00 2.0×103
Table 2. Results from second faecal samples collected following antibiotic
therapy
Placebo group Probiotic group
C. difficile positive 9 11
Toxin-positive 7 5
Diarrhoeal symptoms 6 2
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In 1999, more than 15,000 cases of C. difficile were
reported in the National Health Service (NHS), which would
have cost more than £60 million to treat. If the findings of
this pilot study can be confirmed by a more extensive study,
treatment costs could be reduced by £30 million, and more
than 300,000 hospital-bed days could be made available. If,
with a larger study, the trends from this study are confirmed,
the justification for the use of probiotic therapy for all
patients receiving antibiotic therapy on admission to hospital
would be clearly evident.
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Estudio piloto de Clostridium difficile: efecto del aporte
suplementario de probióticos sobre la incidencia de
diarrea causada por C. difficile
Resumen. La infección de colon por Clostridium difficile, que produce
colitis pseudomembranosa, es una complicación frecuente en las terapias
con antibióticos, especialmente en pacientes de la tercera edad. Se ha sugeri-
do que las bacterias probióticas no patógenas podrían prevenir el desarrollo
de la infección por C. difficile. Este estudio de doble ciego con control me-
diante placebos examina la influencia de la administración de probióticos en
la prevención de diarrea asociada a C. difficile (CDAD) en pacientes de la
tercera edad sometidos a terapia con antibióticos. Se escogieron al azar 150
pacientes consecutivos sometidos a terapia con antibióticos y se les admi-
nistró aleatoriamente durante 20 días un probiótico que contenía
Lactobacillus y Bifidobacterium o un placebo. Tras su ingreso hospitalario,
se anotó su régimen intestinal y se tomó una muestra fecal. El probiótico o
el placebo se administró durante las 72 h primeras del tratamiento con
antibióticos, y se tomó una segunda muestra de heces en el caso de aparecer
diarrea durante la hospitalización o tras el alta médica. De los pacientes
escogidos, 138 completaron el estudio, 69 tratados con antibióticos y pro-
bióticos y 69 solamente con antibióticos. Entre los pacientes que tuvieron
diarrea, se encontró un 2,9% de muestras positivas para la toxina asociada a
C. difficile en el grupo tratado con probióticos, en comparación con el 7,25%
detectado en el grupo control tratado con placebo. Cuando se analizaron
muestras de todos los pacientes (no solamente los que tuvieron diarrea), un
46% de los pacientes tratados con probióticos dieron positivo para la toxina,
en comparación con el 78% del grupo tratado con placebo. [Int Microbiol
2004; 7(1):59–62]
Palabras clave: Clostridium difficile · probiótico · terapia antibiótica ·
diarrea 
Estudo piloto de Clostridium dificile: efeito da 
suplementação com probióticos sobre a incidência 
de diarréia causada por C. difficile
Resumo. A infecção do cólon por Clostridium difficile, derivando em col-
ite pseudomembranosa, é uma complicação comum nas terapias com
antibióticos, especialmente em pacientes na terceira idade. Tem sido sugeri-
do que as bactérias probióticas não patógenas poderiam ter um efeito preven-
tivo sobre o desenvolvimento da infecção por C.difficile. Este estudo, dupla-
mente cego, com controle mediante placebos, examina a influência da admin-
istração de probióticos sobre a prevenção de diarréia associada a C. difficile
(CDAD) em pacientes da terceira idade submetidos à terapia com antibióti-
cos. Foram escolhidos 150 pacientes submetidos à terapia com antibióticos e
se administrou, aleatoriamente, durante 20 dias um probiótico que continha
Lactobacillus e Bifidobacterium ou um placebo. Na admissão hospitalar
foram anotados o regime intestinal do paciente e foram colhidas amostra
fecal. Durante as primeiras 72 horas do tratamento com antibióticos foram
administrados conjuntamente probiótico ou placebo e foi tomada uma segun-
da amostra de fezes, caso o paciente desenvolvesse diarréia durante ou após
a alta médica. Dos pacientes escolhidos, 138 completaram o estudo, 69 trata-
dos com antibióticos e probióticos e 69 somente com antibióticos. Dentre os
pacientes que desenvolveram diarréia, foram encontradas 2,9% de amostras
positivas para a toxina associada a C. difficile no grupo tratado com probióti-
cos, em comparação com 7,25% detectado no grupo controle tratado com
placebo. Quando foram analisadas as amostras de todos os pacientes (não
somente os que desenvolveram diarréia), 46% dos pacientes tratados com
probióticos apresentaram positividade para a toxina em comparação com
78% do grupo tratado com placebo. [Int Microbiol 2004; 7(1):59–62]
Palavras chave: Clostridium difficile · probiótico · terapia antibiótica ·
diarréia
